0
0

Chapter 46. Medications Used for Attention-Deficit/Hyperactivity Disorder

Thomas J. Spencer, M.D.; Joseph Biederman, M.D.; Timothy E. Wilens, M.D.
DOI: 10.1176/appi.books.9781585623921.468068

Sections

Excerpt

Attention-deficit/hyperactivity disorder (ADHD) is one of the major clinical and public health problems in the United States in terms of morbidity and disability in children and adolescents. It is estimated to affect at least 5% of school-age children. Its impact on society is enormous in terms of the financial cost, the stress to families, the impact on schools, and the damaging effects on self-esteem.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
TABLE 46–1. Stimulants
Table Reference Number
TABLE 46–2. Long-acting stimulants
Table Reference Number
TABLE 46–3. Specific noradrenergic reuptake inhibitor
Table Reference Number
TABLE 46–4. Antidepressants
Table Reference Number
TABLE 46–5. Modafinil

References

Adler L, Resnick S, Kunz M, et al: Open-Label Trial of Venlafaxine in Attention Deficit Disorder. Orlando, FL, New Clinical Drug Evaluation Unit Program, 1995
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
Arnold LE, Lindsay RL, Conners CK, et al: A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 14:542–554, 2004
[PubMed]
 
Barkley RA: A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18:137–165, 1977
[PubMed]
 
Barr CL, Wigg K, Malone M, et al: Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder. Am J Med Genet 88:710–713, 1999
[PubMed]
 
Barrickman L, Perry P, Allen AJ, et al: Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:649–657, 1995
[PubMed]
 
Bergman A, Winters L, Cornblatt B: Methylphenidate: effects on sustained attention, in Ritalin: Theory and Patient Management. Edited by Greenhill L, Osman B. New York, Mary Ann Liebert, 1991, pp 223–231
 
Biederman J, Baldessarini RJ, Wright V, et al: A double-blind placebo controlled study of desipramine in the treatment of ADD, I: efficacy. J Am Acad Child Adolesc Psychiatry 28:777–784, 1989
[PubMed]
 
Biederman J, Faraone SV, Keenan K, et al: Further evidence for family genetic risk factors in attention deficit hyperactivity disorder: patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 49:728–738, 1992
[PubMed]
 
Biederman J, Thisted R, Greenhill LL, et al: Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 56:87–93, 1995a
 
Biederman J, Wilens T, Mick E, et al: Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder: effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152:1652–1658, 1995b
 
Biederman J, Wilens T, Mick E, et al: Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:e20, 1999
 
Biederman J, Lopez FA, Boellner SW, et al: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110:258–266, 2002
[PubMed]
 
Biederman J, Quinn D, Weiss M, et al: Efficacy and safety of Ritalin LA, a new, once-daily, extended-release dosage form of methylphenidate hydrochloride, in children with ADHD. Paediatr Drugs 5:833–841, 2003
[PubMed]
 
Biederman J, Swanson J, Wigal SB, et al: Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116:e777–e784, 2005
 
Biederman J, Boellner SW, Childress A, et al: Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62:970–976, 2007a
 
Biederman J, Krishnan S, Zhang Y, et al: Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 29:450–463, 2007b
 
Brown RT, Wynne ME, Slimmer LW: Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. J Clin Psychiatry 45:473–476, 1984
[PubMed]
 
Casat CD, Pleasants DZ, Van Wyck Fleet J: A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull 23:120–122, 1987
[PubMed]
 
Casat CD, Pleasants DZ, Schroeder DH, et al: Bupropion in children with attention deficit disorder. Psychopharmacol Bull 25:198–201, 1989
[PubMed]
 
Conners K, Casat C, Gualtieri CT, et al: Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314–1321, 1996
[PubMed]
 
Connor D, Ozbayrak K, Benjamin S, et al: A pilot study of nadolol for overt aggression in developmentally delayed individuals. J Am Acad Child Adolesc Psychiatry 36:826–834, 1997
[PubMed]
 
Connor D, Glatt SJ, Lopez ID, et al: Psychopharmacology and aggression, I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 41:253–261, 2002
[PubMed]
 
Dillon DC, Salzman IJ, Schulsinger DA: The use of imipramine in Tourette's syndrome and attention deficit disorder: case report. J Clin Psychiatry 46:348–349, 1985
[PubMed]
 
Ding Y, Fowler J, Volkow ND, et al: Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med 36:2298–2305, 1995
[PubMed]
 
Donnelly M, Zametkin AJ, Rapoport JL, et al: Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 39:72–81, 1986
[PubMed]
 
Douglas VI, Barr RG, Amin K, et al: Dosage effects and individual responsivity to methylphenidate in attention deficit disorder. J Child Psychol Psychiatry 29:453–475, 1988
[PubMed]
 
Engber TM, Koury EJ, Dennis SA, et al: Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 241:95–98, 1998
[PubMed]
 
Famularo R, Fenton T: The effect of methylphenidate on school grades in children with attention deficit disorder without hyperactivity: a preliminary report. J Clin Psychiatry 48:112–114, 1987
[PubMed]
 
Faraone SV: Genetics of childhood disorders, XX. ADHD, Part 4: is ADHD genetically heterogeneous? J Am Acad Child Adolesc Psychiatry 39:1455–1457, 2000
[PubMed]
 
Faraone SV, Biederman J, Morley CP, et al: The effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 47:994–1009, 2008
[PubMed]
 
Findling R, Schwartz M, Flannery DJ, et al: Venlafaxine in adults with ADHD: an open trial. J Clin Psychiatry 57:184–189, 1996
[PubMed]
 
Findling RL, Bukstein OG, Melmed RD, et al: A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69:149–159, 2008. Erratum in: J Clin Psychiatry 69:329, 2008
 
Fung YK: Postnatal behavioural effects of maternal nicotine exposure in rats. J Pharm Pharmacol 40:870–872, 1988
[PubMed]
 
Fung YK, Lau YS: Effects of prenatal nicotine exposure on rat striatal dopaminergic and nicotinic systems. Pharmacol Biochem Behav 33:1–6, 1989
[PubMed]
 
Gadow K, Sverd J, Sprafkin J, et al: Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 52:444–455, 1995 (published erratum appears in Arch Gen Psychiatry 52:836, 1995)
 
Gittelman R: Childhood disorders, in Drug Treatment of Adult and Child Psychiatric Disorders. Edited by Klein D, Quitkin F, Rifkin A, et al. Baltimore, MD, Williams & Wilkins, 1980, pp 576–756
 
Gittelman-Klein R: Pharmacotherapy of childhood hyperactivity: an update, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven, 1987, pp 1215–1224
 
Goldman L, Genel M, Bezman RJ, et al: Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 279:1100–1107, 1998
[PubMed]
 
Greenhill L, Halperin J, Abikoff H: Stimulant medications. J Am Acad Child Adolesc Psychiatry 38:503–512, 1998
 
Greenhill L, Findling RL, Swanson JM, et al: A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:E39, 2002
 
Greenhill L, Kollins S, Abikoff H, et al: Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45:1284–1293, 2006a
 
Greenhill L, Muniz R, Ball RR, et al: Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:817–823, 2006b
 
Gutgesell H, Atkins D, Barst R, et al: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 99:979–982, 1999
[PubMed]
 
Heil SH, Holmes HW, Bickel WK, et al: Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149–156, 2002
[PubMed]
 
Hoge SK, Biederman J: A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 47:478–479, 1986
[PubMed]
 
Hornig-Rohan M, Amsterdam J: Venlafaxine vs. Stimulant Therapy in Patients With Dual Diagnoses of ADHD and Depression. Orlando, FL, New Clinical Drug Evaluation Unit Program, 1995
 
Johns JM, Louis TM, Becker RF, et al: Behavioral effects of prenatal exposure to nicotine in guinea pigs. Neurobehav Toxicol Teratol 4:365–369, 1982
[PubMed]
 
Jones GM, Sahakian BJ, Levy R, et al: Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485–494, 1992
[PubMed]
 
Klein R, Mannuzza S: Hyperactive boys almost grown up, III: methylphenidate effects on ultimate height. Arch Gen Psychiatry 45:1131–1134, 1988
[PubMed]
 
Kratochvil CJ, Bohac D, Harrington M, et al: An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:167–170, 2001
[PubMed]
 
Kupietz SS, Winsberg BG, Richardson E, et al: Effects of methylphenidate dosage in hyperactive reading-disabled children, I: behavior and cognitive performance effects. J Am Acad Child Adolesc Psychiatry 27:70–77, 1988
[PubMed]
 
Levin ED, Conners CK, Sparrow E, et al: Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123:55–63, 1996
[PubMed]
 
Lowe TL, Cohen DJ, Detlor J, et al: Stimulant medications precipitate Tourette's syndrome. JAMA 247:1168–1169, 1982
[PubMed]
 
Malhotra S, Santosh P: An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 37:364–371, 1998
[PubMed]
 
McCracken JT, Biederman J, Greenhill LL, et al: Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (ADDERALL XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:673–683, 2003
[PubMed]
 
McGough JJ, Biederman J, Wigal SB, et al: Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:530–538, 2005
[PubMed]
 
McGough JJ, Wigal SB, Abikoff H, et al: A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 9:476–485, 2006
[PubMed]
 
Meck WH, Church RM: Cholinergic modulation of the content of temporal memory. Behav Neurosci 101:457–464, 1987
[PubMed]
 
Mereu G, Yoon K, Boi V, et al: Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 141:395–399, 1987
[PubMed]
 
Michelson D, Faries D, Wernicke J, et al: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001
 
Milberger S, Biederman J, Faraone SV, et al: Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? Am J Psychiatry 153:1138–1142, 1996
[PubMed]
 
Milberger S, Biederman J, Faraone SV, et al: Attention deficit hyperactivity disorder is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:37–44, 1997
[PubMed]
 
Myrick H, Malcolm R, Taylor B, et al: Modafinil: preclinical, clinical, and postmarketing surveillance: a review of abuse liability issues. Ann Clin Psychiatry 16:101–109, 2004
[PubMed]
 
National Institute of Mental Health: Alternative Pharmacology of ADHD, 1996
 
Nemeroff C, DeVane L, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311–320, 1996
[PubMed]
 
Parrott AC, Winder G: Nicotine chewing gum (2 mg, 4 mg) and cigarette smoking: comparative effects upon vigilance and heart rate. Psychopharmacology 97:257–261, 1989
[PubMed]
 
Peeke SC, Peeke HV: Attention, memory, and cigarette smoking. Psychopharmacology 84:205–216, 1984
[PubMed]
 
Pelham WE, Bender ME, Caddell J, et al: Methylphenidate and children with attention deficit disorder. Arch Gen Psychiatry 42:948–952, 1985
[PubMed]
 
Pelham WE, Gnagy EM, Burrows-Maclean L, et al: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001
 
Pelham WE, Burrows-Maclean L, Gnagy EM, et al: Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 13:111–126, 2005a
 
Pelham WE, Manos MJ, Ezzell CE, et al: A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 44:522–529, 2005b
 
Pentikis HS, Simmons RD, Benedict MF, et al: Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 41:443–449, 2002
[PubMed]
 
Perrin JM, Friedman RA, Knilans TK, et al: Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122:451–453, 2008
[PubMed]
 
Pomerleau O, Downey K, Stelson FW, et al: Cigarette smoking in adult patients diagnosed with ADHD. J Subst Abuse 7:373–378, 1996
 
Prince JB, Wilens TE, Biederman J, et al: A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193–204, 2000
[PubMed]
 
Rapport MD, Jones JT, DuPaul GJ, et al: Attention deficit disorder and methylphenidate: group and single-subject analyses of dose effects on attention in clinic and classroom settings. J Clin Child Psychol 16:329–338, 1987
 
Rapport MD, Stoner G, DuPaul GJ, et al: Attention deficit disorder and methylphenidate: a multilevel analysis of dose-response effects on children's impulsivity across settings. J Am Acad Child Adolesc Psychiatry 27:60–69, 1988
[PubMed]
 
Rapport MD, DuPaul GJ, Kelly KL: Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children. Psychopharmacol Bull 25:285–290, 1989
[PubMed]
 
Reimherr F, Hedges D, Strong R, et al: An Open Trial of Venlafaxine in Adult Patients With Attention Deficit Hyperactivity Disorder. Orlando, FL, New Clinical Drug Evaluation Unit Program, 1995
 
Riddle MA, Hardin MT, Cho SC, et al: Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 27:811–814, 1988
[PubMed]
 
Riddle MA, Nelson JC, Kleinman CS, et al: Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30:104–108, 1991
[PubMed]
 
Scheffler RM, Brown TT, Fulton BD, et al: Positive association between attention-deficit/hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics 123:1273–1279, 2009
[PubMed]
 
Silva R, Munoz D, Alpert M: Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis. J Am Acad Child Adolesc Psychiatry 35:352–358, 1996
[PubMed]
 
Singer S, Brown J, Quaskey S, et al: The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 95:74–81, 1994
 
Spencer T, Biederman J, Kerman K, et al: Desipramine in the treatment of children with tic disorder or Tourette's syndrome and attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 32:354–360, 1993a
 
Spencer T, Biederman J, Wilens T, et al: Nortriptyline in the treatment of children with attention deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 32:205–210, 1993b
 
Spencer T, Wilens T, Biederman J, et al: A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434–443, 1995
[PubMed]
 
Spencer T, Biederman J, Wilens T, et al: Pharmacotherapy of attention deficit hyperactivity disorder across the lifecycle: a literature review. J Am Acad Child Adolesc Psychiatry 35:409–432, 1996
[PubMed]
 
Spencer T, Biederman J, Wilens T: Pharmacotherapy of ADHD: a life span perspective, in American Psychiatric Press Review of Psychiatry, Vol 16. Edited by Dickstein LJ, Riba MB, Oldham JM. Washington, DC, American Psychiatric Press, 1997, pp IV87–IV127
 
Spencer T, Biederman J, Wilens T, et al: Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693–695, 1998a
 
Spencer T, Biederman J, Wilens T: Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics 102:501–506, 1998b
 
Spencer T, Biederman J, Coffey B, et al: The 4-year course of tic disorders in boys with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:842–847, 1999
[PubMed]
 
Spencer T, Swanson J, Weidenman M, et al: Pharmacodynamic profile of Ritalin LA, a new extended-release dosage form of Ritalin, in children with ADHD. Presented at the 47th annual meeting of the American Academy of Child and Adolescent Psychiatry, New York, October 2000
 
Spencer T, Biederman J, Heiligenstein J, et al: An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251–265, 2001
[PubMed]
 
Spencer T, Biederman J, Coffey B, et al: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649–656, 2002a
 
Spencer T, Heiligenstein J, Biederman J, et al: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140–1147, 2002b
 
Spencer T, Newcorn J, Kratochvil CJ, et al: Effects of atomoxetine on growth after 2-year treatment in pediatric patients with ADHD. Pediatrics 116:e74–e80, 2005
 
Swanson J, Agler D, Fineberg E, et al: University of California, Irvine, laboratory school protocol for pharmacokinetic and pharmacodynamic studies, in Ritalin: Theory and Practice, 2nd Edition. Edited by Greenhill L, Osman BB. Larchmont, NY, Mary Ann Liebert, 2000, pp 405–430
 
Swanson JM, Greenhill LL, Lopez FA, et al: Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 67:137–147, 2006
[PubMed]
 
Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536, 2002
[PubMed]
 
Vetter VL, Elia J, Erickson C, et al: Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117:2407–2423, 2008
[PubMed]
 
Volkow ND, Wang G, Fowler JS, et al: Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121, 2001
 
Wesnes K, Warburton DM: The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology 82:338–342, 1984
[PubMed]
 
Westfall TC, Grant H, Perry H, et al: Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 14:321–325, 1983
[PubMed]
 
Wigal S, Swanson JM, Feifel D, et al: A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43:1406–1414, 2004
[PubMed]
 
Wigal T, Greenhill L, Chuang S, et al: Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45:1294–1303, 2006
[PubMed]
 
Wilens T, Biederman J: The stimulants. Psychiatr Clin North Am 15:191–222, 1992
[PubMed]
 
Wilens T, Biederman J, Geist DE, et al: Nortriptyline in the treatment of attention deficit hyperactivity disorder: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343–349, 1993
[PubMed]
 
Wilens T, Biederman J, Spencer T, et al: Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 19:257–264, 1999a
 
Wilens T, Biederman J, Spencer T, et al: A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156:1931–1937, 1999b
 
Wilens T, Spencer T, Biederman J, et al: A Controlled Trial of Bupropion SR for Attention Deficit Hyperactivity Disorder in Adults. Boca Raton, FL, New Clinical Drug Evaluation Unit Program, 1999c
 
Wilens T, Haight BR, Horrigan JP, et al: Bupropion XL in adults with ADHD: a randomized, placebo-controlled study. Biol Psychiatry 57:793–801, 2005
[PubMed]
 
Wolraich M, Greenhill LL, Pelham W, et al: Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883–892, 2001
[PubMed]
 
Zametkin A, Rapoport JL: Noradrenergic hypothesis of attention deficit disorder with hyperactivity: a critical review, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven, 1987, pp 837–842
 
Zametkin A, Rapoport JL, Murphy DL, et al: Treatment of hyperactive children with monoamine oxidase inhibitors, I: clinical efficacy. Arch Gen Psychiatry 42:962–966, 1985
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Emerging neuropsychological and neuroimaging literature suggests that the underlying neural substrate of attention-deficit/hyperactivity disorder (ADHD) is a dysfunction of which of the following?
2.
The most commonly abused substance in adolescents and adults with attention-deficit/hyperactivity disorder (ADHD) is
3.
Which of the following medications (brand names) is a long-acting preparation of amphetamine?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 1.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 2.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 3.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 4.  >
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation